The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Compounds of structure R2C=NOH derived from condensation of aldehydes or ketones with hydroxylamine. Oximes from aldehydes may be called aldoximes; those from ketones may be called ketoximes.
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein binds to RXRA protein] which binds to ABCG2 promoter]; [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with NR1I3 protein] results in increased expression of ABCG2 mRNA; [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein binds to RXRA protein] which binds to ABCG2 promoter]] which results in increased expression of ABCG2 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACAA2 mRNA
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of ACACA mRNA [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of ACACA mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of ACACB mRNA
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of ACADS mRNA [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACADS mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACAT1 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACAT2 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACOT12 mRNA
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of ACOT4 mRNA [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACOT4 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACOT6 mRNA 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of ACOT6 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACOT7 mRNA 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of ACOT7 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of ACOT8 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACSL5 mRNA
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of AGPAT2 mRNA [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of AGPAT2 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of APOA5 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of APOB mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of APOC4 mRNA
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CD36 mRNA [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of CD36 mRNA
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CPT2 mRNA [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of CPT2 mRNA
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [NR1I3 protein results in increased expression of CYP2B10 mRNA]; [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime binds to and results in increased activity of NR1I3 protein] which results in increased expression of CYP2B6 mRNA; [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Anisomycin co-treated with NR1I3 protein] results in increased expression of CYP2B6 mRNA; [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with NR1I3 protein alternative form] results in increased expression of CYP2B6 mRNA; [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with NR1I3 protein mutant form] results in increased expression of CYP2B6 mRNA; [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of CYP2B6 mRNA; [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein] which results in increased expression of CYP2B6 mRNA; [Progesterone co-treated with Estradiol] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; allyl isothiocyanate inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of CYP2B6 protein]; allyl isothiocyanate inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; allyl isothiocyanate inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 protein]; allyl isothiocyanate inhibits the reaction [NR1I3 protein promotes the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; ethyl (5-(diethylglycyl)-10,11-dihydro-5H-dibenzo(b,f)azepin-3-yl)carbamate inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; GW 3965 inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; Imidazoles inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; Imidazoles inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 protein]; Ketoconazole inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; lactacystin inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; NR0B1 protein inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6]; NR1I3 mutant form inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; NR1I3 mutant form inhibits the reaction [Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]]; NR1I3 protein promotes the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA] 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B10 mRNA; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 protein
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime binds to NR1I3 protein] which binds to CYP2C8 promoter 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2C8 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of CYP2E1 mRNA
allyl isothiocyanate inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I3 protein promotes the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP3A4 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP3A4 mRNA]; Imidazoles inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP3A4 mRNA]; Imidazoles inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP3A4 protein]; Ketoconazole inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP3A4 mRNA]; lactacystin inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP3A4 mRNA]; NR1I3 protein promotes the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP3A4 mRNA] 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP3A4 mRNA; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP3A4 protein 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of CYP3A4 protein
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of DECR1 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein] which results in increased expression of DHCR24 mRNA
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of FABP1 mRNA
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of FASN mRNA 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime affects the expression of FASN mRNA [Colforsin co-treated with 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime] results in increased expression of FASN mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of FDFT1 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of FDPS mRNA
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [FOXO1 protein binds to G6PC1 promoter]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]; [Progesterone co-treated with Estradiol] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]; Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [FOXO1 protein binds to G6PC1 promoter]]; Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [FOXO1 protein binds to G6PC1 promoter]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]; Progesterone promotes the reaction [Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [FOXO1 protein binds to G6PC1 promoter]]]
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [FOXO1 protein binds to G6PC1 promoter]; [Progesterone co-treated with Estradiol] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of G6PC1 mRNA]; Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [FOXO1 protein binds to G6PC1 promoter]]; Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of G6PC1 mRNA]; NR1I3 mutant form inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of G6PC1 mRNA]; NR1I3 mutant form inhibits the reaction [Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of G6PC1 mRNA]]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of G6PC1 mRNA]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [FOXO1 protein binds to G6PC1 promoter]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of G6PC1 mRNA]; Progesterone promotes the reaction [Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [FOXO1 protein binds to G6PC1 promoter]]] 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of G6PC1 mRNA 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of G6PC1 mRNA; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of G6PC1 protein
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of HADH mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of HADHA mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of HADHB mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of HMGCR mRNA
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [HNF4A protein binds to PCK1 promoter]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]; [Progesterone co-treated with Estradiol] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]; Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [HNF4A protein binds to PCK1 promoter]]; Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [HNF4A protein binds to PCK1 promoter]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]; Progesterone promotes the reaction [Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [HNF4A protein binds to PCK1 promoter]]]
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of IL6 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of LIPC mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of LPIN2 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of LPIN3 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of MCAT mRNA
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [MED1 protein binds to NR1I3 protein alternative form]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [MED1 protein binds to NR1I3 protein]
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of MLXIPL mRNA [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of MLXIPL mRNA
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1H3 protein]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [NCOA1 protein binds to NR1I3 protein alternative form]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [NCOA1 protein binds to NR1I3 protein]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [NR1I3 protein modified form binds to NCOA1 protein]; [Progesterone co-treated with Estradiol] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]; Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [NR1I3 protein binds to NR0B1 protein]; NR0B1 protein inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6]
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1H3 protein]
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of NR1H4 mRNA
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime affects the localization of NR1I3 protein; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime affects the localization of NR1I3 protein mutant form 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein alternative form 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of NR1I3 mRNA 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein mutant form 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime binds to NR1I3 protein 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime binds to and results in increased activity of and results in increased localization of NR1I3 protein mutant form; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime binds to and results in increased activity of NR1I3 protein; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime binds to and results in increased activity of NR1I3 protein alternative form; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime binds to and results in increased activity of NR1I3 protein SNP; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [androstan-3-ol binds to and results in decreased activity of NR1I3 protein alternative form]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [ethyl (5-(diethylglycyl)-10,11-dihydro-5H-dibenzo(b,f)azepin-3-yl)carbamate results in decreased activity of NR1I3 protein]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [Imidazoles binds to and results in decreased activity of NR1I3 protein alternative form]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [PK 11195 results in decreased activity of NR1I3 protein]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [T0901317 results in decreased activity of NR1I3 protein]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein binds to RXRA protein] which binds to ABCG2 promoter]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [MED1 protein binds to NR1I3 protein alternative form]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [MED1 protein binds to NR1I3 protein]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [NCOA1 protein binds to NR1I3 protein alternative form]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [NCOA1 protein binds to NR1I3 protein]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [NCOA3 protein binds to NR1I3 protein]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [NR1I3 protein binds to NR0B1 protein]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [NR1I3 protein modified form binds to NCOA1 protein]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [NR1I3 protein results in increased expression of CYP2B10 mRNA]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [SRC protein binds to NR1I3 protein]; [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime binds to and results in increased activity of NR1I3 protein] which results in increased expression of CYP2B6 mRNA; [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Anisomycin co-treated with NR1I3 protein] results in increased expression of CYP2B6 mRNA; [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with NR1I3 protein alternative form] results in increased expression of CYP2B6 mRNA; [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with NR1I3 protein mutant form] results in increased expression of CYP2B6 mRNA; [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with NR1I3 protein] results in increased expression of ABCG2 mRNA; [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein binds to RXRA protein] which binds to ABCG2 promoter]] which results in increased expression of ABCG2 mRNA; [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein] which results in increased expression of CYP2B6 mRNA; [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein] which results in increased expression of DHCR24 mRNA; [Estradiol co-treated with Progesterone] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein]; [Progesterone co-treated with Estradiol] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]; Acriflavine inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein]; allyl isothiocyanate inhibits the reaction [NR1I3 protein promotes the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I3 protein promotes the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP3A4 mRNA]]; aroclor 1260 inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein alternative form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime affects the localization of NR1I3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein modified form]; Bortezomib inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein]; Clotrimazole inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime binds to and results in increased activity of NR1I3 protein mutant form]; Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]; Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein]; Etoposide inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein]; Imidazoles inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein alternative form]; Meclizine inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein]; metoprine inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein]; NR1I3 mutant form inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of G6PC1 mRNA]; NR1I3 mutant form inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SREBF1 mRNA]; NR1I3 mutant form inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; NR1I3 mutant form inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2C9 mRNA]; NR1I3 mutant form inhibits the reaction [Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of G6PC1 mRNA]]; NR1I3 mutant form inhibits the reaction [Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SREBF1 mRNA]]; NR1I3 mutant form inhibits the reaction [Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]]; NR1I3 mutant form inhibits the reaction [Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2C9 mRNA]]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of G6PC1 mRNA]]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SREBF1 mRNA]]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2C9 mRNA]]; NR1I3 protein promotes the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of CYP3A7 protein]; NR1I3 protein promotes the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; NR1I3 protein promotes the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP3A4 mRNA]; Proflavine inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]; ST 1481 inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein]; T0901317 inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein mutant form]; Trifluridine inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein] 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein alternative form; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein modified form; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein mutant form 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased activity of NR1I3 protein 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime binds to NR1I3 protein; [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime binds to NR1I3 protein] which binds to CYP2C8 promoter
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [HNF4A protein binds to PCK1 promoter]; [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of PCK1 mRNA; [Progesterone co-treated with Estradiol] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of PCK1 mRNA]; Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [HNF4A protein binds to PCK1 promoter]]; Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of PCK1 mRNA]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [HNF4A protein binds to PCK1 promoter]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of PCK1 mRNA]; Progesterone promotes the reaction [Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [HNF4A protein binds to PCK1 promoter]]] 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of PCK1 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of PDSS1 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of PLIN2 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of PPARA mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of RABGGTB mRNA
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein binds to RXRA protein] which binds to ABCG2 promoter]; [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein binds to RXRA protein] which binds to ABCG2 promoter]] which results in increased expression of ABCG2 mRNA
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SCD1 mRNA [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of SCD mRNA; [Progesterone co-treated with Estradiol] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SCD1 mRNA]; Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SCD1 mRNA]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SCD1 mRNA]
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of SLC27A1 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of SLC27A2 mRNA
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SREBF1 mRNA 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of SREBF1 mRNA [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of SREBF1 mRNA; [Progesterone co-treated with Estradiol] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SREBF1 mRNA]; Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SREBF1 mRNA]; NR1I3 mutant form inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SREBF1 mRNA]; NR1I3 mutant form inhibits the reaction [Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SREBF1 mRNA]]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SREBF1 mRNA]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SREBF1 mRNA]
6-bromoindirubin-3'-oxime results in increased expression of and results in increased activity of ABCB1 protein 6-bromoindirubin-3'-oxime results in increased expression of ABCB1 mRNA 6-bromoindirubin-3'-oxime results in increased expression of ABCB1A mRNA; 6-bromoindirubin-3'-oxime results in increased expression of ABCB1A protein
[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of ALDH1 protein; XAV939 inhibits the reaction [[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of ALDH1 protein]
[6-bromoindirubin-3'-oxime co-treated with DHFR mRNA] affects the expression of CTNNB1 protein; broussochalcone A inhibits the reaction [6-bromoindirubin-3'-oxime results in increased expression of CTNNB1 protein]; Methotrexate promotes the reaction [6-bromoindirubin-3'-oxime results in decreased phosphorylation of CTNNB1 protein] [trametinib co-treated with 6-bromoindirubin-3'-oxime] results in decreased expression of CTNNB1 protein
6-bromoindirubin-3'-oxime results in increased expression of CYP1A2 mRNA 6-bromoindirubin-3'-oxime results in increased expression of and results in increased activity of CYP1A2 protein
6-bromoindirubin-3'-oxime promotes the reaction [Paraquat inhibits the reaction [TNFRSF10B protein binds to DDX3X protein]]; 6-bromoindirubin-3'-oxime promotes the reaction [Paraquat results in decreased expression of DDX3X protein modified form]
6-bromoindirubin-3'-oxime results in decreased activity of GSK3B protein 6-bromoindirubin-3'-oxime results in increased phosphorylation of GSK3B protein 6-bromoindirubin-3'-oxime promotes the reaction [Paraquat inhibits the reaction [TNFRSF10B protein binds to GSK3B protein]]; 6-bromoindirubin-3'-oxime promotes the reaction [Paraquat results in decreased expression of GSK3B protein modified form]; Methotrexate promotes the reaction [6-bromoindirubin-3'-oxime results in increased phosphorylation of GSK3B protein] [trametinib co-treated with 6-bromoindirubin-3'-oxime] affects the phosphorylation of GSK3B protein
[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of ITGA6 protein; XAV939 inhibits the reaction [[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of ITGA6 protein]
[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of KRT17 protein; XAV939 inhibits the reaction [[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of KRT17 protein]
[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of NANOG protein; XAV939 inhibits the reaction [[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of NANOG protein]
[Valproic Acid co-treated with 6-bromoindirubin-3'-oxime] results in decreased expression of POU5F1 mRNA [trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of POU5F1 protein; XAV939 inhibits the reaction [[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of POU5F1 protein]
[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of SOX2 protein; XAV939 inhibits the reaction [[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of SOX2 protein]
Aldicarb promotes the reaction [[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with LDN 193189] results in increased expression of MAP2 mRNA]
NRXN1 protein affects the reaction [NLG-1 results in increased susceptibility to Aldicarb]; NRXN1 protein affects the reaction [NRX-1 results in decreased susceptibility to Aldicarb]
Aldicarb inhibits the reaction [[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with LDN 193189] results in increased expression of PAX6 mRNA]
[Calcium results in increased activity of PON1 protein] which results in decreased susceptibility to Aldicarb; [Egtazic Acid results in decreased activity of PON1 protein] which results in increased susceptibility to Aldicarb
cefdinir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid] SLC22A6 protein results in increased uptake of cefdinir
cefdinir inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate] SLC22A8 protein results in increased uptake of cefdinir
diacetylmonoxime inhibits the reaction [cyclohexyl methylphosphonofluoridate binds to and results in decreased activity of ACHE protein]; diacetylmonoxime inhibits the reaction [Paraoxon binds to and results in decreased activity of ACHE protein]; diacetylmonoxime inhibits the reaction [Sarin binds to and results in decreased activity of ACHE protein]; diacetylmonoxime inhibits the reaction [tabun results in decreased activity of ACHE protein]; diacetylmonoxime inhibits the reaction [VX binds to and results in decreased activity of ACHE protein]
diacetylmonoxime inhibits the reaction [Dichlorvos results in decreased activity of BCHE protein]; diacetylmonoxime inhibits the reaction [Isoflurophate results in decreased activity of BCHE protein]
AHR protein affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of CD86 protein]; AHR protein affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of ITGAX protein] indirubin-3'-monoxime binds to and results in increased activity of AHR protein indirubin-3'-monoxime binds to AHR protein
indirubin-3'-monoxime promotes the reaction [tetraarsenic tetrasulfide results in increased expression of AQP9 mRNA]; indirubin-3'-monoxime promotes the reaction [tetraarsenic tetrasulfide results in increased expression of AQP9 protein]
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased expression of CD40 protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 protein] indirubin-3'-monoxime results in decreased expression of CD40 protein
indirubin-3'-monoxime results in increased expression of CD80 protein [Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in increased expression of CD80 protein; indirubin-3'-monoxime promotes the reaction [Lipopolysaccharides results in increased expression of CD80 protein]
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased expression of CD86 protein; AHR protein affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of CD86 protein]; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] results in increased expression of CYP1A1 mRNA; [indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP1A1 mRNA; [indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP1A1 protein indirubin-3'-monoxime results in increased expression of CYP1A1 mRNA indirubin-3'-monoxime results in increased expression of CYP1A1 protein
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] results in decreased expression of HSPA2 mRNA; [indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of HSPA2 mRNA
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of HSPA9 mRNA indirubin-3'-monoxime results in increased expression of HSPA9 mRNA
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased expression of ICAM1 protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] indirubin-3'-monoxime results in decreased expression of ICAM1 protein
indirubin-3'-monoxime results in increased expression of IDO1 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of IDO1 protein]
indirubin-3'-monoxime results in increased expression of IDO2 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of IDO2 protein]
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in increased secretion of IL10 protein; indirubin-3'-monoxime promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] indirubin-3'-monoxime results in decreased secretion of IL10 protein
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased secretion of IL1B protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]
indirubin-3'-monoxime results in decreased expression of IL27 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of IL27 protein]
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased expression of IL6 protein; [Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased secretion of IL6 protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]
AHR protein affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of ITGAX protein]; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased expression of ITGAX protein]
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] results in decreased expression of NFKBIA mRNA
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PTGS2 mRNA; [indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PTGS2 protein
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in increased activity of RELA protein indirubin-3'-monoxime results in decreased activity of RELA protein
indirubin-3'-monoxime results in increased expression of TGFB2 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of TGFB2 protein]
indirubin-3'-monoxime results in increased expression of TGFB3 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of TGFB3 protein]
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased secretion of TNF protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
N(4)-hydroxycytidine results in increased expression of ASNS mRNA 4-nitrobenzylthioinosine inhibits the reaction [N(4)-hydroxycytidine results in increased expression of ASNS mRNA]
[CYB5B protein co-treated with CYB5R3 protein co-treated with MTARC1 protein] results in increased reduction of N(4)-hydroxycytidine; [CYB5B protein co-treated with CYB5R3 protein co-treated with MTARC2 protein] results in increased reduction of N(4)-hydroxycytidine
[CYB5B protein co-treated with CYB5R3 protein co-treated with MTARC1 protein] results in increased reduction of N(4)-hydroxycytidine; [CYB5B protein co-treated with CYB5R3 protein co-treated with MTARC2 protein] results in increased reduction of N(4)-hydroxycytidine
N(4)-hydroxycytidine results in increased expression of HERPUD1 mRNA 4-nitrobenzylthioinosine inhibits the reaction [N(4)-hydroxycytidine results in increased expression of HERPUD1 mRNA]
N(4)-hydroxycytidine results in increased expression of TRIB3 mRNA 4-nitrobenzylthioinosine inhibits the reaction [N(4)-hydroxycytidine results in increased expression of TRIB3 mRNA]
norgestimate binds to and results in decreased activity of AR protein; norgestimate binds to and results in increased activity of AR protein norgestimate affects the localization of AR protein norgestimate results in decreased expression of AR mRNA
[Ethinyl Estradiol co-treated with norgestimate] results in decreased expression of PLAT protein; [Ethinyl Estradiol co-treated with norgestimate] results in increased activity of PLAT protein
Fulvestrant inhibits the reaction [phoxim results in increased expression of PLIN1 protein]; tolclofos-methyl inhibits the reaction [phoxim results in increased expression of PLIN1 protein]
phoxim binds to and results in increased activity of PPARG protein phoxim results in increased expression of PPARG protein Fulvestrant inhibits the reaction [phoxim results in increased expression of PPARG protein]; phoxim binds to and results in increased activity of PPARG protein
Vitamin E inhibits the reaction [phoxim results in increased expression of TNF protein] phoxim results in increased expression of TNF mRNA; phoxim results in increased expression of TNF protein